Kancera AB (publ)
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more
Kancera AB (publ) (KAN) - Total Liabilities
Latest total liabilities as of June 2025: Skr3.58 Million SEK
Based on the latest financial reports, Kancera AB (publ) (KAN) has total liabilities worth Skr3.58 Million SEK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kancera AB (publ) - Total Liabilities Trend (2010–2024)
This chart illustrates how Kancera AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kancera AB (publ) Competitors by Total Liabilities
The table below lists competitors of Kancera AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MetaVia Inc.
NASDAQ:MTVA
|
USA | $8.43 Million |
|
Lord Resources Ltd
AU:LRD
|
Australia | AU$361.05K |
|
Oscar Properties Holding AB
ST:OP
|
Sweden | Skr2.37 Billion |
|
Forbidden Foods Ltd
AU:FFF
|
Australia | AU$1.89 Million |
|
Universal Biosensors Inc
AU:UBI
|
Australia | AU$7.86 Million |
|
Asiabasemetals Inc
V:ABZ
|
Canada | CA$842.85K |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
Indonesia | Rp428.63 Billion |
|
Alakasa Industrindo Tbk
JK:ALKA
|
Indonesia | Rp12.86 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Kancera AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kancera AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kancera AB (publ) (2010–2024)
The table below shows the annual total liabilities of Kancera AB (publ) from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr4.61 Million | -74.35% |
| 2023-12-31 | Skr17.98 Million | +30.03% |
| 2022-12-31 | Skr13.83 Million | +27.19% |
| 2021-12-31 | Skr10.87 Million | +0.47% |
| 2020-12-31 | Skr10.82 Million | -59.83% |
| 2019-12-31 | Skr26.93 Million | +121.21% |
| 2018-12-31 | Skr12.18 Million | -2.70% |
| 2017-12-31 | Skr12.51 Million | -7.35% |
| 2016-12-31 | Skr13.51 Million | +146.21% |
| 2015-12-31 | Skr5.49 Million | -39.92% |
| 2014-12-31 | Skr9.13 Million | +36.43% |
| 2013-12-31 | Skr6.69 Million | -49.18% |
| 2012-12-31 | Skr13.17 Million | -4.82% |
| 2011-12-31 | Skr13.84 Million | +370.04% |
| 2010-12-31 | Skr2.94 Million | -- |